erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the
.
phil lempert: it's affordability. it's convenience. it's not having a lot of waste. people are more concerned about waste than ever before.
.
.
now the country may face a fine of millions of euros after its dereliction was referred to the european court of justice (ecj), the guardian reports.
.